BGPartner advises on Switzerland’s largest financing rounds in 2024
10. February 2025
The Swiss Venture Capital Report 2025 highlights the dynamic growth of the Swiss venture capital market in the past year. BGPartner played a key role in multiple major transactions, advising on some of Switzerland’s largest financing rounds.
In particular BGPartner advised the lead investors OrbiMed, Novo Holdings, Catalio Nexus Fund, LSP Dementia Fund Coöperatieve U.A. (EQT), and SR One on the two biggest financing rounds of 2024:
- Alentis TherapeuticsAG – CHF 160 million (Series D financing round)
- Asceneuron AG – CHF 89 million (Series C financing round)
In addition, BGPartner was involved in other significant transactions, including the Series C extension of Memo Therapeutics AG and the USD 147 million Series B extension of Noema Pharma AG, advising co-lead investors Forbion Growth Opportunities Fund II Coöperatief U.A., Jeito S.L.P., and LSP 7 Coöperatief U.A. (EQT).
Another milestone was BGPartner’s advisory role for the main selling shareholders HBM Healthcare Investments AG, Novo Holdings, and Forbion in the USD 1.25 billion spin-off of Yellow Jersey Therapeutics AG, a subsidiary of Numab Therapeutics AG, to Johnson & Johnson.
These successful transactions highlight BGPartner's leading role in both legal advisory and negotiation matters for complex financing rounds and transactions. A special thanks goes to the exceptional team at BGPartner for their outstanding work.
Find the full Swiss Venture Capital Report 2025.
BGPartner – Mastering Law & Negotiation